Serum Institute of India Pvt. Ltd. revealed a pioneering licensing agreement with the University of Oxford to produce and distribute a chimeric protein-based vaccine designed to combat Meningitis-B, as announced in a press release on Tuesday, April 16. The collaborative effort, projected over five years, aims to tackle the infection known for its severe risks to the brain and spinal cord.
Adar Poonawalla, CEO of Serum Institute, reaffirmed his commitment to global health and underscored the significance of accessible vaccines in the fight against diseases. He stated, “This collaboration epitomizes a shared commitment to global health and highlights the crucial role of accessible vaccines.”
“This collaboration marks a significant stride in our battle against meningitis, ensuring vital protection reaches those in greatest need,” he remarked. The leading vaccine manufacturer aims to expand by supplying vaccines to travellers worldwide.
This development follows Serum Institute’s MenFive vaccine obtaining pre-qualification from the World Health Organization in July 2023, cementing the company’s role as a pivotal player in addressing meningitis outbreaks on a global scale.
Simon Warner, Head of Licensing & Ventures – Life Sciences at Oxford University Innovation, praised the agreement as a testament to Oxford’s commitment to vaccine innovation. He emphasized the university’s dedication to developing effective vaccines, underscoring the significance of academic licensing and fruitful commercial partnerships in tackling global health challenges.
“The agreement for the Men-B vaccine with the Serum Institute of India exemplifies yet another instance of vaccine innovation stemming from the University of Oxford. Oxford’s unwavering commitment and investment in creating efficacious, deployable vaccines will safeguard millions of lives. Academic licensing and productive commercial partnerships play a crucial role in addressing global health challenges,” Warner stated.
Read More: Click Here
